Burning Rock Biotech (BNR) Receivables - Other (2019 - 2026)

Burning Rock Biotech (BNR) has reported Receivables - Other for 8 consecutive years, with $1.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Other fell 22.14% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (down 22.14% YoY), while the FY2025 annual figure was $1.8 million, down 7.32% from the prior year.
• Receivables - Other came in at $1.8 million for Q1 2026 at Burning Rock Biotech, up from $1.7 million in the prior quarter.
• The five-year high for Receivables - Other was $8.1 million in Q2 2023, with the low at $1.7 million in Q4 2025.
• Average Receivables - Other over 5 years is $4.1 million, with a median of $3.0 million recorded in 2024.
• Across the five-year window, Receivables - Other increased 22.03% in 2023 and slumped 68.36% in 2024, its largest moves.
• Year by year, Receivables - Other stood at $5.9 million in 2022, then slumped by 46.19% to $3.2 million in 2023, then slumped by 38.95% to $1.9 million in 2024, then declined by 10.08% to $1.7 million in 2025, then rose by 6.26% to $1.8 million in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $1.8 million, $1.7 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.